CS
AVIR icon

Credit Suisse’s Atea Pharmaceuticals AVIR Stock Holding History

Credit Suisse’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-76,764
Closed -$257K – 3170
2023
Q1 		$257K Buy
76,764
+2,430
+3% +$9.86K ﹤0.01% 3048
2022
Q4 		$358K Buy
74,334
+19,842
+36% +$100K ﹤0.01% 2947
2022
Q3 		$310K Buy
54,492
+450
+0.8% +$3.44K ﹤0.01% 3068
2022
Q2 		$383K Buy
54,042
+37,772
+232% +$258K ﹤0.01% 3008
2022
Q1 		$118K Sell
16,270
-2,991
-16% -$20.3K ﹤0.01% 3461
2021
Q4 		$172K Buy
19,261
+1,863
+11% +$29K ﹤0.01% 4308
2021
Q3 		$610K Buy
17,398
+5,420
+45% +$150K ﹤0.01% 3680
2021
Q2 		$257K Buy
+11,978
New +$360K ﹤0.01% 4179

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse's AVIR Position: Q2 2023 in Review

Credit Suisse sold out of Atea Pharmaceuticals (AVIR) in Q2 2023, closing a stake of 76,764 shares — an estimated $257K sold.

Credit Suisse first reported a position in AVIR in Q2 2021 and held it in 8 quarters. The position peaked at $610K in Q3 2021. 133 funds tracked by Wall St. Rank hold AVIR as of Q2 2023.

  • Credit Suisse reported no remaining Atea Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Credit Suisse sold 76,764 Atea Pharmaceuticals shares in Q2 2023, an estimated $257K.
  • Credit Suisse first reported a position in Atea Pharmaceuticals in Q2 2021 and held it in 8 quarters.
  • Credit Suisse's Atea Pharmaceuticals position peaked at $610K in Q3 2021.
  • 133 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2023.

Based on Credit Suisse's 13F filing for Q2 2023, filed 11 Aug 2023.